Physician profile
John Podeszwa
NPI 1841291697
$12,089.30
in general payments reported to CMS, 2019-2025
32 companies · $3,143 in 2025
The $3,143 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $824 · 2021: $1,458 · 2022: $1,841 · 2023: $1,790 · 2024: $2,198 · 2025: $3,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,046 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,046.07 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,870.29 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,801.20 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $721.25 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $712.91 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $685.12 | 2019-2025 | |
| Ardelyx, INC. | $612.93 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $553.63 | 2020-2023 | |
| Celgene Corporation | $399.10 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $376.38 | 2019-2025 | Linzess |
| Qol Medical, LLC | $331.56 | 2019-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $331.02 | 2019-2024 | Rebyota |
| Pfizer INC. | $295.23 | 2019-2025 | |
| Braintree Laboratories, INC. | $280.97 | 2019-2023 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $269.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $268.83 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $249.94 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $230.67 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.90 | 2023-2024 | Cyltezo |
| Organon LLC | $146.09 | 2023-2025 | Hadlima, Renflexis |
| Redhill Biopharma INC. | $132.02 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $115.36 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $88.13 | 2025 | Iqirvo |
| Allergan, INC. | $77.86 | 2019-2020 | |
| Lilly USA, LLC | $63.22 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $52.18 | 2019-2021 | |
| Capsovision, INC. | $50.13 | 2024-2025 | Capsocam Plus |
| Novo Nordisk INC | $40.97 | 2022-2025 | Wegovy |
| Celltrion USA INC. | $39.49 | 2024 | Vegzelma |
| Daiichi Sankyo INC. | $24.37 | 2019-2020 | |
| Alfasigma USA, INC. | $24.12 | 2020 | |
| Ucb, INC. | $20.12 | 2019 | |
| Amgen INC. | $19.29 | 2023 | Avsola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Podeszwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.